Health Care [ 7/12 ] | Biotechnology [ 35/73 ]
NASDAQ | Common Stock
Anavex Life Sciences Corp. operates as a biopharmaceutical company.
It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer.
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome.
Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors.
The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.
The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies.
Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.13 Decreased by -1.23% | -0.15 Increased by +12.27% |
| Feb 5, 25 | -0.14 Decreased by -27.27% | -0.17 Increased by +17.65% |
| Nov 25, 24 | -0.14 Decreased by -16.67% | -0.17 Increased by +17.65% |
| Aug 6, 24 | -0.14 Increased by 0.00% | -0.16 Increased by +12.50% |
| May 9, 24 | -0.13 Increased by +23.53% | -0.11 Decreased by -18.18% |
| Feb 7, 24 | -0.11 Increased by +35.29% | -0.14 Increased by +21.43% |
| Nov 27, 23 | -0.12 Increased by +33.33% | -0.15 Increased by +20.00% |
| Aug 8, 23 | -0.14 Increased by +12.50% | -0.17 Increased by +17.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -11.20 M Decreased by -6.16% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -12.11 M Decreased by -40.47% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -11.62 M Decreased by -14.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.21 M Decreased by -8.28% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -10.55 M Increased by +19.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.62 M Increased by +33.53% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.15 M Increased by +29.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.28 M Increased by +8.79% | Decreased by N/A% Decreased by N/A% |